



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

IOLCP/CGC/2016
02 May 2016

The General Manager
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051

The General Manager
BSE Limited.
Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai


Sub: Press Release

Dear Sir,

Please find attached herewith press release regarding Audited Financial Results of the Company for the Quarter/ Financial Year ended 31 March 2016.

Thanking you

Yours faithfully,
for IOL Chemicals and Pharmaceuticals Limited



[Krischan Singla]
Vice President & Company Secretary

For immediate release

Press Release

Impressive Results by IOL Chemicals and Pharmaceuticals Limited

IOL Chemicals and Pharmaceuticals Limited a leading manufacturer of bulk drugs and specialty chemicals posted an impressive performance for the quarter and year ended 31 March 2016.

Net sales revenue increased by **90%** during the quarter ended 31 March 2016 to Rs 142.47 crores from Rs 75.27 crores during the corresponding quarter of the previous year. The company has earned profit after tax during the quarter ended 31 March 2016 of Rs 1.13 crores against loss of Rs 28.06 crores during the corresponding quarter of the previous year. The operating profit for the quarter ended 31 March 2016 went up to Rs 17.72 crores as against operating loss of Rs 16.19 crores reported in the corresponding quarter ended 31 March 2015.

The net sales revenue of the company went up by **51%** to Rs 581.62 crores during the year FY 16 in comparison to Rs 386.02 crores reported in the previous year. The company has able to reduce its losses to Rs 40.03 crores during the year under review from Rs 66.65 crores incurred during the previous year.

Further the company has completed its de-bottlenecking /re-engineering project of its Ibuprofen plant by which capacity of Ibuprofen plant increased from 6000 TPA to 6200 TPA.

During the year the company has received US Food and Drug Administration approval for its Ibuprofen manufacturing facilities situated at Barnala, Punjab.

The company is in process of adding new pharma products in near future, which will add value to exiting portfolio and enabling to broaden its global market.


About IOL Chemicals and Pharmaceuticals Limited (IOLCP)

Company was established in 1986, listed on Bombay Stock Exchange (Code: 524164) and National Stock Exchange (Code: IOLCP) is India's one of the leading generic pharmaceutical company, and is significant player in the specialty chemicals space with world class facilities. IOLCP has wide presence across major therapeutic categories like, Pain Management, Anti-diabetic, Anti hypertensive, Anti Convulsants, etc.

IOLCP's product portfolio includes APIs; Ibuprofen, specialty chemicals such as Iso Butyl Benzene (IBB), Ethyl acetate, Mono Chloro Acetic Acid and Acetyl Chloride.

Company is world's only largest backward integrated Ibuprofen producer with an installed capacity of 6200TPA, manufacturing all intermediates stages and Key Starting Materials at one location. The company has DSIR approved R&D which is fully equipped to validate existing processes. State of art Multipurpose plant provides significant upside opportunity for further development of APIs.

The Central and State Government approved Effluent Treatment Plant (ETP) **was set up with zero effluent discharge system alongwith 17 MW captive Co-Generation plant for self reliance.**



IOLCP's overseas customers are spread out across several countries including Brazil, Argentina, China, Hungary, USA, Chile, Peru, Colombia, South Africa, Thailand, Australia, Netherlands, Iran and many other Middle East Countries. Products are sold primarily to Branded Generic formulators both in India & Overseas.

The company is continuous winner of National Energy Conservation award for 10 years. Company is an - ISO 9001:2008, ISO 14001:2004 and OHSAS 18001:2007

For more information on IOLCP, please visit <http://www.iolcp.com>

